United States of America ex rel. Steven M. Camburn v. Novartis Pharmaceuticals Corporation

District Court, S.D. New York·Decided September 24, 2020·No. 1:13-cv-03700·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK UNITED STATES OF AMERICA; the States of CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, FLORIDA, GEORGIA, HAWAII, ILLINOIS, INDIANA, IOWA, LOUISIANA, MASSACHUSETTS, MICHIGAN, MINNESOTA, MONTANA, NEVADA, NEW No. 13 Civ. 3700 (KMW) JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, OKLAHOMA, RHODE ISLAND, STIPULATED TENNESSEE, TEXAS, VIRGINIA, WASHINGTON CONFIDENTIALITY and WISCONSIN; the DISTRICT OF COLUMBIA, AGREEMENT AND THE CITY OF CHICAGO and THE CITY OF NEW PROTECTIVE ORDER YORK; ex rel., STEVEN M. CAMBURN Plaintiffs and Relator, vs. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant. THE HONORABLE GABRIEL W. GORENSTEIN, UNITED STATES MAGISTRATE JUDGE: WHEREAS, all of the parties to this action (collectively, the “Parties” and each individually, a “Party”) request that this Court issue a protective order pursuant to Federal Rule of Civil Procedure 26(c) to protect the confidentiality of nonpublic and competitively sensitive information that they may need to disclose in connection with discovery in this action or that they may otherwise produce or disclose to the opposing Party; WHEREAS, the Parties, through their counsel, as evidenced by their signatures below, agree to the following terms; and WHEREAS, this Court finds that good cause exists for issuance of an appropriately tailored confidentiality order governing the pretrial phase of this action; IT IS HEREBY ORDERED that the Parties to this action, their respective officers, agents, servants, employees, and attorneys, any other person in active concert or participation with any of the foregoing, and all other persons with actual notice of this Order will adhere to the

following terms, upon pain of contempt: 1. With respect to “Discovery Material” (i.e., information of any kind produced or disclosed in the course of discovery or otherwise in this action) that a person has designated as “Confidential” pursuant to this Order, no person subject to this Order may disclose such Confidential Discovery Material to anyone else except as expressly permitted hereunder: 2. The Party or person producing or disclosing Discovery Material (each, “Producing Party”) may designate as Confidential only the portion of such material that it reasonably and in good faith believes consists of: (a) previously non-disclosed1 financial information (including without

limitation profitability reports or estimates, percentage fees, design fees, royalty rates, minimum guarantee payments, sales reports, and sale margins); (b) previously non-disclosed material relating to ownership or control of any non-public company; (c) previously non-disclosed business plans, product-development information, or marketing plans;

1 For purposes of this protective order, previously non-disclosed information includes information disclosed under seal or pursuant to a protective order. (d) previously non-disclosed information related to formulas, patterns, programs, plans, devices, methods, techniques, or processes used for the preparing, manufacturing, or processing of pharmaceutical or biological products; (e) any information protected from disclosure by applicable trade secrets law,

including the Uniform Trade Secrets Act (adapted by the vast majority of states) and the Defend Trade Secrets Act (18 U.S.C. § 1839); (f) health care information subject to protection under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), Privacy Rule, 45 C.F.R. §§ 160 and 164, and/or other applicable state or federal law concerning confidential health information; (g) personal data subject to protection under the General Data Protection Regulation (GDPR) and/or other applicable foreign national data protection laws;

(h) a trade secret or other confidential research, development or information; (i) any information of a personal or intimate nature regarding any individual; or (j) any other category of information given confidential status by this Court after the date of this Order. Information to be treated as “Confidential” under this order includes all materials labeled as confidential that have been produced to the United States Attorney’s Office for the Southern District of New York in response to any Civil Investigative Demand or subpoenas in connection with the investigation related to this action. 3. With respect to the Confidential portion of any Discovery Material other than deposition transcripts and exhibits, the Producing Party or its counsel may designate such portion as “Confidential” by: (a) stamping or otherwise clearly marking as “Confidential” the protected portion in a manner that will not interfere with legibility or audibility; and (b)producing for future public use another copy of said Discovery Material with the confidential

information redacted. 4. A Producing Party or its counsel may designate deposition exhibits or portions of deposition transcripts as Confidential Discovery Material either by: (a) indicating on the record during the deposition that a question calls for Confidential information, in which case the reporter will bind the transcript of the designated testimony in a separate volume and mark it as “Confidential Information Governed by Protective Order;” or (b) notifying the reporter and all counsel of record, in writing, within 30 days after a deposition has concluded, of the specific pages and lines of the transcript that are to be designated “Confidential,” in which case all counsel receiving the transcript will be responsible for marking the copies of the designated

transcript in their possession or under their control as directed by the Producing Party or that person’s counsel. During the 30-day period following a deposition, all Parties will treat the entire deposition transcript as if it had been designated Confidential. 5. If at any time before the termination of this action a Producing Party realizes that it should have designated as Confidential some portion(s) of Discovery Material that it previously produced without limitation, the Producing Party may so designate such material by notifying all Parties in writing. Thereafter, all persons subject to this Order will treat such designated portion(s) of the Discovery Material as Confidential. 6. Nothing contained in this Order will be construed as: (a) a waiver by a Party or person of its right to object to any discovery request; (b) a waiver of any privilege or protection; or (c) a ruling regarding the admissibility at trial of any document, testimony, or other evidence. 7. Where a Producing Party has designated Discovery Material as

Confidential, other persons subject to this Order may disclose such information only to the following persons: (a) the Parties to this action, their insurers and their external auditors; (b) counsel retained specifically for this action, including any paralegal, clerical, or other assistant that such outside counsel employs and assigns to this matter; (c) outside vendors or service providers (such as copy-service providers and document-management consultants) that counsel hire and assign to this matter;

Free access — add to your briefcase to read the full text and ask questions with AI

United States of America ex rel. Steven M. Camburn v. Novartis Pharmaceuticals Corporation, (S.D.N.Y. 2020).

United States of America ex rel. Steven M. Camburn v. Novartis Pharmaceuticals Corporation (United States of America ex rel. Steven M. Camburn v. Novartis Pharmaceuticals Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Lugosch v. Pyramid Co. of Onondaga
435 F.3d 110 (Second Circuit, 2006)